Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Mink Therapeutics Inc <INKT.OQ> expected to post a loss of 60 cents a share - Earnings Preview
Mink Therapeutics Inc INKT.OQ INKT.O is expected to show no change in quarterly revenue when it reports results on August 13 for the period ending June 30 2026
LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 60 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 256.2% above its last closing price of $10.95
This summary was machine generated August 11 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's